Feb 18 (Reuters) - Medtronic ( MDT ) beat Wall Street

estimates for quarterly profit on Tuesday, on strong demand for

its heart and diabetes devices.

Investors have high expectations of medical device makers as

they continue to benefit from healthy demand for non-urgent

surgeries, especially among older Americans, over the last few

quarters.

The company, however, kept its annual profit forecast

unchanged in the range of $5.44 to $5.50 per share. Analysts, on

average, estimate the company's annual profit at $5.45,

according to data compiled by LSEG.

Shares of the company fell 1.4% to $91.49 in premarket

trading.

For the quarter, sales in its cardiovascular segment rose

3.7% to $3.04 billion, meeting estimates.

Its diabetes segment grew 8.4% to $694 million, above

estimates of $681.8 million.

On an adjusted basis, the medical device maker reported

third-quarter profit per share of $1.39, compared to analysts'

estimate of a profit of $1.36 per share.